Fibrosis is a common pathological process underlying a wide range of chronic diseases affecting the lungs, liver, kidneys, heart, and other organs. Despite considerable progress in understanding fibrotic mechanisms, developing effective antifibrotic therapies remains challenging.

One of the major obstacles is the ability to reproduce the complexity of human fibrotic tissue in experimental models. Fibrosis involves not only fibroblast activation and excessive extracellular matrix (ECM) deposition, but also changes in tissue mechanics, cellular interactions, and inflammatory signaling.

In the first webinar of our new series, Preci introduces its Fibrosis, Metabolic & Chronic Diseases (FMC) platform and demonstrates how human-derived in vitro models can support fibrosis research and drug discovery.

Moving Beyond Conventional Fibrosis Models

Fibroblast-to-myofibroblast transition (FMT) is a central process in fibrogenesis, frequently associated with TGF-β signaling, increased α-smooth muscle actin expression, and the production of ECM proteins.

However, fibrotic disease progression cannot be fully explained by individual signaling pathways. The composition, organization, and mechanical properties of the extracellular matrix also influence cellular behavior and therapeutic responses.

These interactions highlight the importance of experimental systems that incorporate both relevant human cells and tissue-derived ECM.

Human-Derived ECM and Multicellular Assembloids

Preci has developed human-derived ECM-based models designed to reproduce important features of the tissue microenvironment.

By combining human ECM with primary stromal cells and additional cell populations, these systems can form multicellular microtissues, or assembloids, suitable for studying cell–matrix interactions and fibrotic responses.

The platform supports the development of disease-specific models and the incorporation of multiple cell types while maintaining compatibility with established analytical methods.

Integrated Assays for Fibrosis Research

Preci’s FMT platform combines complementary analytical approaches to characterize fibrotic processes and evaluate potential therapeutic interventions.

Transcriptomic analysis supports model characterization, target investigation, and the identification of biomarkers associated with fibrotic responses.

Biomarker assays, including qPCR-based panels and immunoassays, enable the measurement of molecular changes associated with fibroblast activation and disease progression.

High-content imaging provides quantitative assessment of cellular phenotypes, including α-smooth muscle actin expression and changes in lipid accumulation.

Matrix mechanics assays evaluate the functional consequences of fibrotic remodeling through measurements of tissue stiffness and viscoelastic properties.

Together, these workflows enable fibrosis research across molecular, cellular, and tissue-functional levels.

Experimental Applications

The webinar presents several examples demonstrating the platform’s capabilities:

  • Transcriptomic analysis of lung fibrosis models to distinguish responses associated with ECM composition and TGF-β stimulation.
  • Imaging-based assays investigating fibrogenic activation and donor-dependent cellular responses.
  • Functional matrix mechanics measurements evaluating changes in tissue stiffness following fibrogenic stimulation and pathway inhibition.

These approaches can support biomarker discovery, target validation, model characterization, and antifibrotic compound evaluation.

Watch the Webinar

Discover how Preci integrates human-derived ECM, primary cells, multicellular models, and complementary analytical workflows to advance translational fibrosis research.

Watch the full webinar below.

To discuss disease-specific fibrosis models, assay development, or custom research projects, contact the Preci team.